Hyperglycemia increases expression of platelet-derived growth factor (PDGF)-␤ receptor and potentiates chemotaxis to PDGF-BB in human aortic vascular smooth muscle cells (VSMCs) via PI3K and ERK/MAPK signaling pathways. The purpose of this study was to determine whether increased activation of protein kinase C (PKC) isoforms had a modulatory effect on the PI3K and ERK/MAPK pathways, control of cell adhesiveness, and movement. All known PKC isoforms were assessed but only PKC ␣ and PKC ␤II levels were increased in 25 mmol/L glucose. However, only PKC ␤II inhibition affected (decreased) PI3K pathway and MAPK pathway activities and inhibited PDGF-␤ receptor upregulation in raised glucose, and specific MAPK inhibition was required to completely block the effect of glucose. In raised glucose conditions, activity of the ERK/MAPK pathway, PI3K pathway, and PKC ␤II were all sensitive to aldose reductase inhibition. Chemotaxis to PDGF-BB (360 pmol/L), absent in 5 mmol/L glucose, was present in raised glucose and could be blocked by PKC ␤II inhibition. Formation of lamellipodia was dependent on PI3K activation and filopodia on MAPK activation; both lamellipodia and filopodia were eliminated when PKC ␤II was inhibited. FAK phosphorylation and cell adhesion were reduced by PI3K inhibition, and although MAPK inhibition prevented chemotaxis, it did not affect FAK phosphorylation or cell adhesiveness. In conclusion, chemotaxis to PDGF-BB in 25 mmol/L glucose is PKC ␤II -dependent and requires activation of both the PI3K and MAPK pathways. Changes in cell adhesion and migration speed are mediated mainly through the PI3K pathway. (Circ Res. 2005;96:197-206.) 
P remature atherosclerosis occurs not only in diabetic subjects 1 but also in those with impaired glucose tolerance who experience intermittent periods of elevated glucose. 2 Atheroma formation involves migration of the vascular smooth muscle cells (VSMCs) into the subintimal space, 3 and a change from a nonmotile, contractile phenotype to a proliferative, secretory phenotype. In vitro, several cell types including fibroblasts, monocytes, and endothelial cells express the platelet-derived growth factor (PDGF)-␤ receptor and migrate to a physiological concentration of PDGF-BB if serum starved 4 ; PDGF-BB is elevated in diabetes 5 and in atherosclerosis. 6 We have previously shown that aortic VSMC migration to PDGF-BB occurs in raised glucose conditions (Ͼ9 mmol/L glucose) without prior serum starvation. 7 PDGF-␤ receptor antibodies block this migration in vitro, 7 and in an in vivo mouse model they reduce significantly the extent of atheroma formation. 8 Cell movement can be directional (migration) or random. Moving cells polarize 9 ; the leading edge becomes broad, forming a lamellipodium, and presents direction-sensing microspikules (filopodia), whereas the actin cytoskeleton organizes along the long axis of the cell to facilitate movement. 10 Movement also requires the laying down at the front of the cell and removal at the back of small punctate structures, focal adhesions, that link the cell to its basement membrane and contain integrins and PDGF-␤ receptors. 11 Most analysis techniques for migration do not separate the speed and direction components or allow direct cell observation. Using the Dunn chemotaxis chamber, we have shown that VSMC exposed to raised glucose in a PDGF-BB gradient present morphological alterations associated with migration, with increased levels of f-actin and with filopodia at the leading edge. 7, 12 It is known that the serine/threonine kinase protein kinase C (PKC) can also affect VSMC chemotaxis. 13 PKC is associated with PDGF-␤ receptor upregulation and, like the Ras-Raf-MEK1/2-ERK1/2 MAPK and PI3K pathways, is sensitive to elevated glucose levels. 7, 14 PKC consists of approximately 12 isoforms in three subclasses: conventional (cPKC-␣, -␤I, -␤II, and -␥), novel (nPKC-␦, -⑀, -, -, and -), and atypical (aPKC-and -/). Conventional isoforms are Ca 2ϩ -dependent and require diacylglycerol (DAG) and phosphatidylserine for their activation, novel isoforms are Ca 2ϩ -independent, and atypicals require only the presence of phosphatidylserine. 15 Elevated glucose levels produce increased flux through the sorbitol pathway with resultant de novo synthesis of DAG, which activates PKC isoforms 16 and Ras. 17 DAG is present in human aortic VSMCs, and its level increases in raised glucose conditions with a peak being reached by 3 days. 18 The rate-limiting enzyme of the sorbitol pathway, aldose reductase, is widely distributed in those mammalian tissues susceptible to diabetic complications and its inhibition prevents complications in galactosemic animal models. 19 The response to aldose reductase inhibitors (ARI) in clinical trials has been disappointing, 20 indicating that indirect effects of long-term exposure to glucose (advanced glycation end-product formation or o-glycosylation) 21 bypass this pathway's control.
We have recently shown that glucose-potentiated VSMC chemotaxis and the associated morphological changes are dependent on the PI3K and Ras/ERK MAPK pathways and also on cross-talk between these pathways 12 ; both pathways also control PDGF-␤ receptor upregulation and migration in raised glucose. 7 In view of that, the object of this investigation was to determine at which point(s) PKC modifies glucose-potentiated PI3K and/or MAPK activity during human aortic VSMC migration (direction, speed and adhesion) induced by PDGF-BB.
Materials and Methods

Chemicals
The following chemicals were used: D-glucose and L-glucose (BDH, UK); recombinant human PDGF-BB (Insight Biotechnology Ltd, UK); LY294002, wortmannin, rapamycin, and rhodamine-phalloidin (Sigma, UK); PD98059, calphostin C and H7 (Calbiochem); farnesyltransferase inhibitor (FTI) H-D-Trp-D-Met-p-chloro-D-Phe-Gla-NH 2 (Bachem, UK); alrestatin (Tocris, UK); active Akt1, active PKC ␤II , and PKC lipid activator (Upstate); cognate peptides to PKC isoforms (Santa Cruz Biotechnology); and LY379196 and sorbinil (gifts from Eli Lilly and Pfizer, respectively).
For an expanded Materials and Methods, see the online data supplement available at http://circres.ahajournals.org.
Results
PKC ␤II Is Elevated in VSMC in 25 mmol/L Glucose After 24 Hours
All PKC isoforms except PKC ␥ and PKC were identified in human primary aortic VSMCs (Table 1) . After 24 hour in 25 mmol/L glucose, the protein level of only two isoforms PKC ␤II (ϩ55%: PϽ0.01 versus 5 mmol/L glucose) and PKC ␣ (ϩ20%: PϽ0.05 versus 5 mmol/L glucose) increased significantly. The level of serine/threonine phosphorylation of PKC ␤II (ϩ94%: PϽ0.01 versus 5 mmol/L glucose) and PKC ␣ (ϩ20%: PϽ0.05 versus 5 mmol/L
TABLE 1. Determination of the PKC Isoforms Present in Human Aortic-Derived VSMCs in 5 and 25 mmol/L Glucose Conditions
Quantification of immunoblots for PKC isoforms, from cell lysates. Autoradiographs were scanned by densitometry and the signal level of 25 mmol/L (24 hours) vs. 5 mmol/L glucose alone is presented in tabular form for total protein and Ser/Thr phosphorylation level; nϭ4 independent experiments. Where Student t test analysis showed significant differences (PϽ0.05) in signal level percentage changes in 25 mmol/L conditions are shown. glucose) also increased significantly after 24 hours in 25 mmol/L glucose. Phosphorylation of PKC ␤II showed a significant increase only in the membranous fraction ( Figure 1A : ϩ74%, PϽ0.001 versus 5 mmol/L glucose). The small increase in PKC ␣ phosphorylation occurred across both the cytoplasmic and membranous cellular fractions (see online Figure B available in the online data supplement). Activation of PKC ␤II in an isoform specific kinase assay ( Figure 1B ) showed a significant increase in activity in 25 mmol/L glucose after 24 hours in the membranous fraction (ϩ160%, PϽ0.01 versus 5 mmol/L glucose alone).
Chemotaxis to PDGF-BB in 25 mmol/L Glucose Is Sorbitol Pathway and PKC ␤II -Dependent
To determine whether the PKC isoforms elevated in 25 mmol/L glucose had a functional effect on VSMCs, chemotaxis assays were undertaken. Chemotaxis without serum starvation does not occur to a physiological level of PDGF-BB (360 pmol/L) in 5 mmol/L glucose (PϭNS) but does occur in 25 mmol/L glucose (PϽ0.01: Table 2 ). The aldose reductase inhibitors (ARI) sorbinil and alrestatin, which prevent de novo synthesis of DAG, prevented chemotaxis to PDGF-BB. The general PKC inhibitor calphostin C and the specific PKC ␤II inhibitor LY379196 used at a concentration (200 nmol/L) where PKC ␤I was unaffected blocked chemotaxis (see online Figure C and online Table A ). Microinjection experiments showed that only affinity-purified antibodies to the PKC ␤II isoform blocked chemotaxis in 25 mmol/L glucose ( Table 2) ; this could be prevented by preincubating the antibody with a molar excess of its cognate peptide. Chemotaxis assay result for human VSMCs (S3) cultured in 5 mmol/L glucose without prior serum starvation and set up in 5 or 25 mmol/L glucose in a 360 pmol/L PDGF-BB gradient within the Dunn chemotaxis chamber. Where age-and source-matched cells were available, speed was determined. P value equals the Rayleigh test probability that chemotaxis occurred. Cell speeds are presented as meanϮSEM, nϭ31 to 61 cells from 3 to 5 independent experiments in each case. No. of cells migrating in the direction of the source well is presented as a percentage of the total no. of cells present in the field of view: cell viability being greater than 95% in all cases. Results of treatments in 5 mmol/L glucose are not shown. For controls, see online Table A . ND indicates not determined.
Inhibitors used were as follows: aldose reductase (sorbinil, 500 mol/L; alrestatin, 20 mol/L), PKC (calphostin C, 50 nmol/L), and PKC ␤II (LY379196, 200 nmol/L). Microinjection concentrations: antibody (0.1 mg/mL) and active peptide (50 ng/mL). Preabsorbed antibody experiments: antibodies were preabsorbed using an ϫ30 molar excess of their cognate peptides before microinjection.
PKC ␤II in PDGF-BB Treated VSMCs: Activation/Phosphorylation Is Sorbitol Pathway-Dependent, Protein Level Is mTOR Pathway-Dependent
Chemotaxis to PDGF-BB in 25 mmol/L glucose is PKC ␤IIand sorbitol pathway-dependent. We have previously shown that glucose-potentiated chemotaxis depends on PI3K and MAPK pathways 7 ; therefore, the relationship of these pathways to PKC ␤II regulation was examined.
Global PKC ␤II Phosphorylation
To examine the degree of phosphorylation, serine/threonine phosphorylation of the protein was measured ( Figure 1C ). Phosphorylation was unaffected by inhibitors in 5 mmol/L glucose, but increased after 24 hours in 25 mmol/L glucose (ϩ94%, PϽ0.001 versus 5 mmol/L glucose alone). Reductions in phosphorylation were found in 25 mmol/L glucose after 24 hours with PI3K, mTOR, and sorbitol pathway inhibitors (PϽ0.01 versus 25 mmol/L glucose alone). Similar results to those above were found when the degree of phosphorylation on the Ser660 residue of PKC ␤II (located at the cofactor binding site) 22 was examined with a significant increase after 24 hours in 25 mmol/L glucose (ϩ103%, PϽ0.001 versus 5 mmol/L glucose alone; Figure 1D ).
PKC ␤II Protein Level
In 5 mmol/L glucose, the total protein level depended on the PI3K-related mTOR pathway because mTOR inhibition (rapamycin) decreased it by 24% (PϽ0.01: Figure 1E ). PKC ␤II in 5 mmol/L glucose was unaltered by sorbinil (ARI), PD98059 (MEK1/2 inhibitor), or by the farnesyltransferase inhibitor (FTI), which prevents prenylation of Ras (MAPK pathway). The increased level of PKC ␤II in 25 mmol/L glucose (ϩ55%, versus 5 mmol/L glucose, PϽ0.01) was under similar control but sorbinil or alrestatin (not shown) were also able to decrease the total PKC ␤II level and the effects of PI3K inhibition were significant.
PKC Inhibition Prevents 25 mmol/L Glucose-Potentiated PDGF-␤ Receptor Upregulation in PDGF-BB-Treated VSMCs
Investigation was made into possible PKC involvement in the pathways responsible for PDGF-␤ receptor upregulation in conditions of 25 mmol/L glucose plus 360 pmol/L PDGF-BB ( Figure 2A ). In 5 mmol/L glucose, MAPK and PI3K dependence were demonstrated (PϽ0.05 versus untreated for both inhibitors). Receptor upregulation associated with 25 mmol/L glucose for 24 hours (ϩ101%, PϽ0.01 versus 5 mmol/L glucose alone) was decreased significantly by PI3K, MAPK, general PKC, PKC ␤II , or aldose reductase inhibition. However, only MAPK or aldose reductase inhibition returned the receptor back to the 5 mmol/L glucose level (PϽ0.01 versus 25 mmol/L and PϭNS versus 5 mmol/L glucose alone). That PKC inhibition controlled the receptor at the transcriptional level was confirmed by RT-PCR ( Figure 2B ). The significant increase in receptor mRNA found in 25 mmol/L glucose (ϩ83%, PϽ0.01) was inhibited partially by general PKC inhibition but totally by PKC ␤II inhibition (PϽ0.01 versus 25 mmol/L glucose alone).
PKC Inhibition Prevents 25 mmol/L Glucose-Potentiated Akt and ERK Activation in PDGF-BB-Treated VSMCs
Pathways upregulating the PDGF-␤ receptor in 25 mmol/L glucose include PKC, PI3K, and MAPK but the relationship between these pathways has not yet been determined.
PI3K Pathway
Akt (a downstream target of PI3K) phosphorylation increased after 24 hours in 25 mmol/L glucose (ϩ54%, PϽ0.05 versus 5 mmol/L glucose; Figure 3A ). Calphostin C caused a modest (nonsignificant) decrease in the 25 mmol/L glucosepotentiated phosphorylation level but LY379196 and the ARI both reduced it significantly (PϽ0.05 versus 25 mmol/L glucose alone). However, only the ARI decreased the level to that found in 5 mmol/L glucose. To confirm that the weak effect of PKC ␤II inhibition on Akt phosphorylation was significant with respect to activity, an Akt kinase assay was undertaken ( Figure 3B ). LY379196 did not affect Akt activation in 5 mmol/L glucose but reduced the ability of Akt to phosphorylate its target molecule, GSK-3, in 25 mmol/L glucose (ϩ81% in 25 mmol/L glucose versus 5 mmol/L glucose alone, PϽ0.01; LY379196 treatment, ϩ45%, PϽ0.05 versus 5 or 25 mmol/L glucose alone). PKC appears to act upstream of PI3K in the pathways leading to PDGF-␤ receptor upregulation in 25 mmol/L glucose.
MAPK Pathway
ERK1/2 (a downstream target in the MAPK pathway) phosphorylation increased in 25 mmol/L glucose after 24 hours (ϩ95%, PϽ0.01 versus 5 mmol/L glucose; Figure 3C ). Calphostin C and LY379196 had a modest (nonsignificant) effect on the 25 mmol/L glucose-potentiated increase in phosphorylation, but sorbinil reduced the level (PϽ0.05 versus 25 mmol/L glucose alone). To identify if LY379196 modulated ERK phosphorylation, an ERK kinase assay was undertaken ( Figure 3D ). LY379196 did not affect ERK activation in 5 mmol/L glucose but reduced the ability of ERK to phosphorylate its target molecule ELK-1 in 25 mmol/L glucose (ϩ189% in 25 mmol/L glucose versus 5 mmol/L glucose alone, PϽ0.01; LY379196 treatment, PϽ0.05 versus 5 or 25 mmol/L glucose alone). It would appear that PKC ␤II acts upstream of ERK/MAPK in the pathways leading to PDGF-␤ receptor upregulation in 25 mmol/L glucose.
To confirm that ERK phosphorylation was a downstream target of PKC ␤II and Akt activation, microinjection experiments were undertaken ( Figure 3E and Figure 3F ). Injection of activated Akt caused a significant increase in ERK phosphorylation in 5 mmol/L glucose conditions. In 25 mmol/L glucose and the presence of alrestatin (20 mol/ L), injection of activated Akt ( Figure 3E ) could partially restore the level of ERK phosphorylation (PϽ0.05 versus 5 mmol/L or 25 mmol/L glucose). In the presence of the PKC ␤II inhibitor, LY379196 (200 nmol/L), injection of activated Akt could totally recover the level of ERK phosphorylation (PϭNS versus 25 mmol/L glucose; Figure 3E ). Injection of activated PKC ␤II significantly increased ERK phosphorylation in both 5 and 25 mmol/L conditions ( Figure  3F ). The effect in 25 mmol/L glucose was partly lost in the presence of the ARI and totally lost in the presence of the MAPK inhibitor ( Figure 3F ). The microinjection of activated PKC ␤II was sufficient to induce chemotaxis in 5 mmol/L glucose conditions (without prior serum starvation) and restored chemotaxis lost because of aldose reductase inhibition in 25 mmol/L glucose conditions ( Table 2 ). 
PKC ␤II Inhibition Prevents 25 mmol/L Glucose-Potentiated Filopodia Formation
Migrating cells show characteristic changes in their ultrastructure. Membrane ruffles (lamellipodia) distribute around the rim of a nonmigrating cell: this is seen in a representative micrograph ( Figure 4A ) for a cell in 5 mmol/L glucose within a 360 pmol/L PDGF-BB gradient. In 25 mmol/L glucose, the cell polarizes with a lamellipodium localizing along the front and prominent actin bundles stretching along the long axis of the cell ( Figure 4B ). Characteristic filopodia (linked with direction sensing) protrude from the lamellipodium (see inset). PDGF-␤ receptors are detected along filopodia in 25 mmol/L glucose ( Figure 4C ). With PKC ␤II inhibition filopodia, lamellipodium and f-actin alignment are lost ( Figure 4D ).
PKN Signaling to Lamellipodia Is PKC ␤II -Dependent in 25 mmol/L Glucose
Protein kinase N (PKN) is involved in formation of lamellipodia. 23 We have recently shown that MAPK inhibitors affect filopodia but not lamellipodia formation in VSMCs. 12 To clarify the role PKC has on lamellipodia formation, the effect of the pathway inhibitors on PKN was assessed ( Figure 5A ). The Ser/Thr phosphorylation of PKN was significantly increased in 25 mmol/L glucose (ϩ69%, PϽ0.01 versus 5 mmol/L glucose). MAPK inhibition had no effect but PI3K, PKC ␤II , or aldose reductase inhibition significantly decreased the activation level (PϽ0.01 versus 25 mmol/L glucose alone for all).
PKC ␤II -Dependent Pathways Control Cell Speed in 25 mmol/L Glucose
Chemotaxis to PDGF-BB (360 pmol/L) was demonstrated in the presence of 25 mmol/L glucose. Migration also has a speed component. Speed in 25 mmol/L glucose is significantly reduced compared with matched cells (same source and passage) set up in 5 mmol/L glucose (random movement) in the chamber (Table  2) . Speed was unaffected in 25 mmol/L glucose by MAPK inhibition (by chemical inhibitor or microinjected antibody; see online Table A) , or by microinjection of conventional PKC isoform antibodies other than PKC ␤II . PKC ␤II isoform microinjection or LY379196 exposure prevented chemotaxis and restored speed to that found in 5 mmol/L glucose.
PKC ␤II -Dependent Pathways Control Adhesion in 25 mmol/L Glucose
Changes in cellular adhesion may account for the decreased speed found in 25 mmol/L glucose; therefore, an adhesion assay was undertaken ( Figure 5B ). In 5 mmol/L glucose, MAPK (PD98059 or FTI), PKC ␤II , or aldose reductase inhibition did not alter adhesion level, but PI3K inhibition caused a significant decrease in adhesion (LY294002, Ϫ48%; wortmannin, Ϫ42%; PϽ0.05 versus 5 mmol/L glucose alone). In 25 mmol/L glucose, adhesiveness increased significantly (ϩ66%, PϽ0.05 versus 5 mmol/L glucose). MAPK inhibition had no effect, whereas PI3K inhibition showed a similar percentage reduction (LY294002, Ϫ48%; wortmannin, Ϫ54%), as found in 5 mmol/L glucose. PKC ␤II inhibition and ARI, ineffective in 5 mmol/L glucose, significantly reduced adhesion in 25 mmol/L glucose. Similar results to those in Figure 5B were found when phosphospecific antibodies were microinjected into cells subsequently set up in an adhesion assay ( Figure 5C ). Again a pPKC ␤II dependency was found in 25 mmol/L glucose conditions for control of adhesion. An antibody to phosphorylated FAK (a known component of focal adhesions) inhibited adhesion in both 5 mmol/L and 25 mmol/L glucose conditions. Microinjection of pAkt did not alter adhesion, indicating that this branch of the PI3K pathway is not involved in adhesion control ( Figure 5C ). 
PKC ␤II -Dependent Pathways Signal to Focal Adhesions in 25 mmol/L Glucose
Cellular adhesion is mainly controlled through focal adhesions, and focal adhesion kinase (FAK) can act as a marker of intracellular signaling to the substratum. The level of FAK phosphorylation increased in 25 mmol/L glucose (ϩ69%, PϽ0.05 versus 5 mmol/L glucose; Figure 5D ). MAPK inhibition had no effect on 25 mmol/L glucose-potentiated FAK phosphorylation, but the PI3K, PKC ␤II , and aldose reductase inhibitors all restored it to 5 mmol/L glucose levels (PϽ0.05 versus 25 mmol/L glucose alone; Figure 5D ). A representative micrograph is shown ( Figure 4E ) for a cell stained with phospho-FAK antibody (green) in 25 mmol/L glucose. The phospho-FAK(Tyr576/577) staining was punctate in nature and localized mainly to the cell membrane: this distribution is in keeping with that expected for focal adhesions. Microinjection of cells in 25 mmol/L glucose with affinity-purified phospho-FAK antibody did not alter PDGF-␤ receptor level (online Figure D) nor prevent chemotaxis to PDGF-BB (Table 2) ; however, the cell speed (in 25 mmol/L glucose) was restored to that found in 5 mmol/L glucose.
Discussion
This study has revealed significant differences in both the glucose-and PKC-dependency of PI3K and MAPK activation in human VSMCs ( Figure 6 ). Most PKC isoforms were detected in primary explant-derived human aortic VSMCs including PKC-␣, -␤I, -␤II, -␦, -⑀, and -. The time frame for the 25 mmol/L glucose experiments was short in terms of the chronicity of diabetes and was associated with upregulation of the conventional isoforms of PKC (PKC-␣ and -␤II). We found that the total level of PKC ␤II was regulated by mTOR-dependent pathways in VSMCs; mTOR acts on the serine/arginine-rich splicing factor (SRp40) that controls splicing of the PKC ␤ gene, altering production away from PKC ␤I toward PKC ␤II . 24 The PI3K/Akt pathway regulates mTOR-dependent signaling. 25 Aldose reductase inhibitors prevent increased flux through the sorbitol pathway, reduce PI3K/Akt activation, and mTORdependent signaling. PKC ␤II is upregulated in many cell types in The PKC ␤II /PI3K pathway controls adhesion and lamellipodium formation and indirectly controls filopodia formation. We have previously shown that Akt activates the MAPK pathway under these conditions 12 but the point (below Ras and above ERK1/2) where this occurs has not been demonstrated. response to glucose 26 ; exceptionally, one group has reported small decreases in PKC ␤II activity in rat aorta, 27, 28 but cell cycle synchronization through serum starvation in those experiments meant that the S phase-dependent decrease in PKC ␤II 28 may have affected the results. In the present study in human aortic VSMCs, both PKC ␣ and PKC ␤II were activated, but only PKC ␤II demonstrated a major increase in the membrane fraction and was involved in glucose-potentiated chemotaxis.
We have previously shown that regulation of the PDGF-␤ receptor depends on both the PI3K and MAPK pathways 7 with mainly, but not exclusively, PI3K signaling to the MAPK pathway. 12 Aldose reductase inhibition and blockade of PKC ␤II prevent PDGF-␤ receptor increases in rat VSMCs 14 ; in this study, we confirm the effect in human aortic VSMCs and demonstrate that receptor protein expression is controlled at the transcriptional level. We demonstrated that PKC ␤II inhibition suppresses, but does not abolish, activation of Akt and ERK in high glucose; PKC ␤II inhibition has no effect on ERK activity in normal glucose (not shown). DAG can activate the MAPK pathway directly, 17 and in our experiments, sorbitol pathway inhibition or MAPK inhibition (upstream and downstream of DAG, respectively) removed all of the high glucose effect on PDGF-␤ receptor protein and chemotaxis. Under similar glucose conditions, migration of coronary VSMCs was also sorbitol pathway-dependent. 13 Here, we show that high glucose induces both PKC ␤IIindependent and PKC ␤II -dependent signaling to the MAPK pathway. PKC ␤II -dependent signaling to MAPK occurs indirectly via PKC ␤II -stimulated phosphorylation in the PI3K/Akt pathway with subsequent cross-talk to the ERK/MAPK pathway. 12 The PKC ␤II -independent signaling involves direct DAG activation of Ras upstream in the ERK/MAPK pathway bypassing both PKC ␤II and the PI3K/Akt pathway.
Previously, we showed that MAPK pathway inhibition reduces filopodia but not lamellipodia formation 12 ; in this study, PKC ␤II inhibition affects both. The effect of PKC ␤II on MAPK activation (via PI3K) may account for its effect on filopodia. To confirm that lamellipodia formation was PKC ␤II / PI3K-dependent, we measured PKN activity, which is involved in lamellipodia formation, 23 and demonstrated it was PKC ␤II /PI3K-dependent and MAPK-independent. Speed of movement was higher in 5 mmol/L glucose (random movement) than in 25 mmol/L glucose (migration), provided cells were age-and source-matched. With PKC ␤II inhibition (chemical inhibitor or microinjected antibody), migration was abolished and speed restored to that for 5 mmol/L glucose. Specific inhibitors of the MAPK pathway (PD98059 or microinjected anti-pERK antibody) prevented migration in high glucose without altering speed, indicating that speed is controlled at a higher point in the pathways. Cell adhesion in 25 mmol/L glucose was regulated in a similar manner to speed with PKC ␤II inhibition reducing adhesion to that found with 5 mmol/L glucose levels, and MAPK inhibition having no effect. Focal adhesions, which control inside to outside cell signaling, contain PDGF-␤ receptors and integrins linked via their cytoplasmic components to signaling molecules such as FAK. 29 In this study, the phosphorylation site to which the FAK antibody was directed depends on PI3K signaling. 30 We demonstrated that in 25 mmol/L glucose this signaling to FAK can be modified by input from PKC ␤II . As demonstrated by phospho-FAK antibody microinjection, it is this PKC ␤II / PI3K-dependent signaling to FAK that controls cell speed by altering adhesion (see Figure 6 ).
In summary, we have demonstrated that in glucose conditions that occur intermittently in diabetes, human aortic VSMCs migrate in a concentration of PDGF-BB such as is present in atherosclerotic plaques. This glucose-potentiated migration is sorbitol pathway-dependent for activation of the ERK/MAPK pathway and for PKC ␤II signaling to the PI3K pathway. We have shown in this study that in addition to PKC ␤II -independent signaling to the MAPK pathway from increased flux through the sorbitol pathway, there is PKC ␤IIdependent signaling to MAPK. Increases in PDGF-␤ receptor level depend on PKC ␤II signaling to both the PI3K and ERK/MAPK pathways in these conditions. PKC ␤II influence on PI3K leads to alterations in adhesion, FAK phosphorylation, cell speed, and lamellipodia formation, but the ERK/ MAPK pathway is not involved in these processes.
